Security
Palisade Bio, Inc. Common Stock · PALI
PALINASDAQCommon stockCurrentCIK 1357459Updated Nov 2, 2026
Name history
PALISADE BIO, INC. · through Oct 30, 2026Seneca Biopharma, Inc. · through Apr 26, 2021Neuralstem, Inc. · through Jan 23, 2020
PALI price & chart
Loading TradingView…
NASDAQ:PALI on TradingView ↗About the company
We are a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. Our lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including fibrostenotic Crohn’s disease (“FSCD”) and ulcerative colitis (“UC”).
In the news
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI) News provided by Purcell & Lefkowitz LLP Oct 20, 2025, 11:50 ET Share this article Share to X Share this article Share to X NEW YORK , Oct. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz ↗
Recent filings
SCHEDULE 13G/A - filed by Commodore Capital LP regarding PALISADE BIO, INC.
SCHEDULE 13G/A - filed by Soleus Capital Master Fund, L.P. regarding PALISADE BIO, INC.
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
144 filing
Show 5 more recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.03, 5.07, 9.01
S-8 filing
SCHEDULE 13G - filed by Soleus Capital Master Fund, L.P. regarding PALISADE BIO, INC.
EFFECT filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,973,000Source | 9,336,000Source | 127,315,000Source | 6,667,000Source | 12,871,000Source | 133,315,000Source | 8,190,000Source | 12,652,000Source | 134,344,000Source | 10,880,000Source | 14,052,000Source | 15,763,000Source |
| Property, Plant and Equipment, NetUSD | 0Source | 3,000Source | — | 1,000Source | 4,000Source | — | 2,000Source | 5,000Source | 0Source | 3,000Source | 10,000Source | 10,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,227,000Source | 8,040,000Source | 125,172,000Source | 5,417,000Source | 11,353,000Source | 132,628,000Source | 7,230,000Source | 11,276,000Source | 133,385,000Source | 9,821,000Source | 12,432,000Source | 12,383,000Source |
| Assets, CurrentUSD | 6,828,000Source | 8,870,000Source | 127,260,000Source | 6,447,000Source | 12,312,000Source | 133,243,000Source | 7,887,000Source | 12,013,000Source | 134,221,000Source | 10,494,000Source | 13,328,000Source | 14,733,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,601,000Source | 830,000Source | 1,588,000Source | 1,030,000Source | 959,000Source | 615,000Source | 657,000Source | 737,000Source | 836,000Source | 673,000Source | 896,000Source | 2,350,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 113,000Source | — | 22,000Source | 142,000Source | — | 53,000Source | 170,000Source | 0Source | 84,000Source | 198,000Source | 300,000Source |
| Other Assets, NoncurrentUSD | 119,000Source | 324,000Source | 0Source | 171,000Source | 387,000Source | 17,000Source | 222,000Source | 438,000Source | 68,000Source | 273,000Source | 490,000Source | 694,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,761,000Source | 2,728,000Source | 5,567,000Source | 4,047,000Source | 2,922,000Source | 5,953,000Source | 2,859,000Source | 2,588,000Source | 4,964,000Source | 3,388,000Source | 2,739,000Source | 3,284,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 91,000Source | 11,000Source | 1,735,000Source | 48,000Source | 9,000Source | 1,674,000Source | 43,000Source | 8,000Source | 1,594,000Source | 27,000Source | 93,000Source | 30,000Source |
| Additional Paid in CapitalUSD | 146,945,000Source | 139,195,000Source | 292,910,000Source | 143,528,000Source | 139,051,000Source | 288,011,000Source | 143,460,000Source | 135,087,000Source | 280,509,000Source | 143,407,000Source | 132,724,000Source | 121,637,000Source |
| Retained Earnings (Accumulated Deficit)USD | — | 132,600,000Source | — | 141,000,000Source | -129,100,000Source | — | 138,200,000Source | -125,000,000Source | — | 135,900,000Source | 121,500,000Source | 109,200,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,212,000Source | 6,608,000Source | 121,748,000Source | 2,620,000Source | 9,949,000Source | 127,362,000Source | 5,331,000Source | 10,064,000Source | 129,380,000Source | 7,492,000Source | 11,313,000Source | 12,479,000Source |
| Liabilities and EquityUSD | 6,973,000Source | 9,336,000Source | 127,315,000Source | 6,667,000Source | 12,871,000Source | 133,315,000Source | 8,190,000Source | 12,652,000Source | 134,344,000Source | 10,880,000Source | 14,052,000Source | 15,763,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,478,000Source | 2,681,000Source | 5,246,000Source | 3,970,000Source | 2,836,000Source | 5,620,000Source | 2,777,000Source | 2,467,000Source | 4,636,000Source | 3,236,000Source | 2,586,000Source | 3,012,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 122,000Source | — | 24,000Source | 130,000Source | — | 58,000Source | 125,000Source | 0Source | 90,000Source | 121,000Source | 105,000Source |
| Accounts Payable, CurrentUSD | 1,426,000Source | 366,000Source | 1,835,000Source | 1,374,000Source | 514,000Source | 2,696,000Source | 745,000Source | 459,000Source | 767,000Source | 1,105,000Source | 698,000Source | 1,759,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | — | — | 24,000Source | — | — | 58,000Source | — | 0Source | 90,000Source | 211,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,220,000Source | 1,509,000Source | 3,136,000Source | 2,066,000Source | 1,555,000Source | 2,802,000Source | 1,856,000Source | 1,670,000Source | 2,187,000Source | 1,240,000Source | 831,000Source | 574,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Other Liabilities, Noncurrent | —Source | — | — | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,297,000Source | 69,000Source | 3,955,000Source | 652,000Source | 624,000Source | 1,032,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,890,000Source | -2,333,000Source | -10,847,000Source | -12,193,000Source | -11,133,000Source | -13,360,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | -4,000Source | -10,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | 4,000Source | 10,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 25,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 3,133,000Source | -258,000Source | 134,440,000Source | 9,582,000Source | 11,186,000Source | 15,258,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -757,000Source | -2,591,000Source | 123,593,000Source | -2,611,000Source | 49,000Source | 1,888,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,000Source | 1,000Source | 10,000Source | 14,000Source | 14,000Source | 12,000Source |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 85,000Source | 92,000Source | 4,775,000Source | 60,000Source | 4,291,000Source | 57,000Source | 3,924,000Source | 633,000Source | 606,000Source | 1,032,000Source |
| DepreciationUSD | — | — | — | — | — | — | 0Source | 1,000Source | 3,000Source | 3,000Source | 4,000Source | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | 59,000Source | 2,426,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | 0Source | 0Source | -4,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,528,000Source | 1,456,000Source | 4,798,000Source | 1,168,000Source | 4,351,000Source | 1,360,000Source | 7,864,000Source | 5,796,000Source | 6,202,000Source | 8,764,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | 0Source | 2,000Source | 1,000Source | 1,000Source | 10,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,868,000Source | -3,487,000Source | -10,574,000Source | -2,784,000Source | -9,600,000Source | -2,230,000Source | -16,781,000Source | -14,438,000Source | -12,300,000Source | -14,260,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,868,000Source | -3,487,000Source | — | -2,784,000Source | — | -2,230,000Source | — | -14,438,000Source | -12,316,000Source | -14,548,000Source |
| Nonoperating Income (Expense)USD | — | — | 54,000Source | 106,000Source | 1,124,000Source | 59,000Source | 1,148,000Source | 80,000Source | 1,275,000Source | 421,000Source | 770,000Source | 1,461,000Source |
| Operating ExpensesUSD | — | — | 2,922,000Source | 3,593,000Source | 12,198,000Source | 2,843,000Source | 10,748,000Source | 2,310,000Source | 18,056,000Source | 14,859,000Source | 13,320,000Source | 15,721,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 59,000Source | 112,000Source | 1,124,000Source | 61,000Source | 1,149,000Source | 81,000Source | 1,285,000Source | 433,000Source | 785,000Source | 158,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 3,250,000Source | 0Source | 128,219,000Source | 8,435,000Source | 9,419,000Source | 14,401,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | 0Source | 225,000Source | 410,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0.5Source | 0Source | 0Source | 0Source | 0Source | — | 300,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | 500,000Source | 0Source | — | — | — | 0Source | 250,000Source | — |
| Operating Income (Loss)USD | — | — | -2,922,000Source | -3,593,000Source | -11,698,000Source | -2,843,000Source | -10,748,000Source | -2,310,000Source | -18,056,000Source | -14,859,000Source | -13,070,000Source | -15,721,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 59,000Source | 112,000Source | 1,124,000Source | 61,000Source | 1,149,000Source | 81,000Source | 1,285,000Source | 433,000Source | 785,000Source | 158,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,868,000Source | -3,487,000Source | -10,574,000Source | -2,784,000Source | -9,600,000Source | -2,230,000Source | -16,781,000Source | -14,438,000Source | -12,300,000Source | -14,260,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.38Source | -2.32Source | -0.05Source | -0.58Source | -0.05Source | -0.47Source | -0.3Source | -10.19Source | -1.8Source | -16.53Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.38Source | -2.32Source | -0.05Source | -0.58Source | -0.05Source | -0.47Source | -0.3Source | -10.19Source | -1.8Source | -16.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 7,473,898Source | 1,500,409Source | 211,381,969Source | 4,797,196Source | 209,663,966Source | 4,795,646Source | 55,669,821Source | 1,416,471Source | 6,840,213Source | 880,311Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 7,473,898Source | 1,500,409Source | 211,381,969Source | 4,797,196Source | 209,663,966Source | 4,795,646Source | 55,669,821Source | 1,416,471Source | 6,840,213Source | 880,311Source |
| Interest Expense (non-operating)USD | — | — | — | — | 0Source | 2,000Source | 1,000Source | 1,000Source | 10,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | — | 3,000Source |
| General and Administrative ExpenseUSD | — | — | 1,528,000Source | 1,456,000Source | 4,798,000Source | 1,168,000Source | 4,351,000Source | 1,360,000Source | 7,864,000Source | 5,796,000Source | 6,202,000Source | 8,764,000Source |
| Interest ExpenseUSD | — | — | 5,000Source | 6,000Source | — | 2,000Source | — | 1,000Source | — | 12,000Source | 15,000Source | 13,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,868,000Source | -3,487,000Source | — | -2,784,000Source | — | -2,230,000Source | — | -14,438,000Source | -12,316,000Source | -14,548,000Source |
| Nonoperating Income (Expense)USD | — | — | 54,000Source | 106,000Source | 1,124,000Source | 59,000Source | 1,148,000Source | 80,000Source | 1,275,000Source | 421,000Source | 770,000Source | 1,461,000Source |
| Operating ExpensesUSD | — | — | 2,922,000Source | 3,593,000Source | 12,198,000Source | 2,843,000Source | 10,748,000Source | 2,310,000Source | 18,056,000Source | 14,859,000Source | 13,320,000Source | 15,721,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | — | 0Source | 225,000Source | 410,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 0Source | 0Source | 0.5Source | 0Source | 0Source | 0Source | 0Source | — | 300,000Source | — |
| Research and Development Expense | — | — | — | —Source | —Source | — | —Source | — | — | — | — | — |
Offerings
Registration 333-295815
Registration 333-290568
- Gross proceeds
- 119999999.87
- Net proceeds
- 111599999.88
- Deal price
- 0.7
- Shares
- 171428571
- Offering price
- $0.700000
- Ticker
- PALI
Registration 333-287578
Filing attachments
pali-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 pali-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy resu…
Read attachment ↗ex107.htm · S-8 · 2026-06-10
Calculation of Filing Fee Tables S-8 PALISADE BIO, INC. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ────────────────────────────────────────────────…
Read attachment ↗ex107.htm · S-3 · 2026-05-12
Calculation of Filing Fee Tables S-3 PALISADE BIO, INC. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Agg…
Read attachment ↗ex4-10.htm · S-3 · 2026-05-12
Exhibit 4.10 PALISADE BIO, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________ PALISADE BIO, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “ Agreement ”), dated as of [●], between PALISADE BIO, INC., a Delaware corporation (the “ Company ”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as wa…
Read attachment ↗ex4-5.htm · S-3 · 2026-05-12
Exhibit 4.5 PALISADE BIO, INC., Iss u er AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗ex4-8.htm · S-3 · 2026-05-12
Exhibit 4.8 PALISADE BIO, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________ PALISADE BIO, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “ Agreement ”), dated as of [●], between PALISADE BIO, INC., a Delaware corporation (the “ Company ”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agen…
Read attachment ↗